MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance

Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA), allowing MRM to advance MH002 into the phase 2b STARFISH-UC clinical trial in patients with mild-to-moderate ulcerative colitis (UC). UC is a type of inflammatory bowel disease (IBD) […] The post MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance appeared first on Pharmafile.

Continue reading →